{"disease":{"id":"astrocytic-tumor","name":"astrocytic tumor"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06620926","title":"Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma","phase":"","overall_status":"COMPLETED","enrollment_count":811,"lead_sponsor_name":"asmaa salama ibrahim","has_results":false},{"nct_id":"NCT05465954","title":"Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06776250","title":"Study of How Safe and Effective Tarlatamab is in Brain Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT01967758","title":"Phase I Study of Safety and Immunogenicity of ADU-623","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Providence Health & Services","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}